MGX vs. IMTX, MESO, RLAY, PRME, SRRK, CRGX, RGNX, VALN, ITOS, and HLVX
Should you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Immatics (IMTX), Mesoblast (MESO), Relay Therapeutics (RLAY), Prime Medicine (PRME), Scholar Rock (SRRK), CARGO Therapeutics (CRGX), REGENXBIO (RGNX), Valneva (VALN), iTeos Therapeutics (ITOS), and HilleVax (HLVX). These companies are all part of the "biological products, except diagnostic" industry.
Metagenomi (NASDAQ:MGX) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
Immatics received 17 more outperform votes than Metagenomi when rated by MarketBeat users. However, 90.00% of users gave Metagenomi an outperform vote while only 72.22% of users gave Immatics an outperform vote.
Metagenomi has higher earnings, but lower revenue than Immatics.
In the previous week, Metagenomi had 3 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Metagenomi and 1 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat Metagenomi's score of 0.38 indicating that Immatics is being referred to more favorably in the news media.
Metagenomi has a net margin of 0.00% compared to Immatics' net margin of -107.80%. Metagenomi's return on equity of 0.00% beat Immatics' return on equity.
64.4% of Immatics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Metagenomi currently has a consensus price target of $17.83, suggesting a potential upside of 179.52%. Immatics has a consensus price target of $16.00, suggesting a potential upside of 45.06%. Given Metagenomi's higher possible upside, equities analysts plainly believe Metagenomi is more favorable than Immatics.
Summary
Metagenomi beats Immatics on 8 of the 15 factors compared between the two stocks.
Get Metagenomi News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Metagenomi Competitors List
Related Companies and Tools
